Lotus Ventures Inc. (CSE:J) (Frankfurt: LV9) (the “Company” or “Lotus”), an Okanagan based cannabis cultivator with a recently licensed state-of-the-art facility, launched its new consumer brand – Lotus Cannabis Co. (“Lotus Cannabis” or the “Brand”). Lotus Cannabis is the only cannabis brand owned and operated by Lotus Ventures Inc. and the Company intends to continue to be listed on the Canadian Securities Exchange under the ticker symbol “J”.
In addition to the Brand, Lotus’ new website is now up and running at (lotuscannabis.ca). The new branding, packaging and website reflect the team’s commitment to quality. The new Lotus website makes our focus apparent, and our packaging design represents the targeting of discerning cannabis connoisseurs. The Company anticipates growing a proprietary product, unique to the Canadian market, and will issue a separate press release for its official strain launch.
Closing of Financing
Lotus has closed a non-brokered private placement financing by issuance of an additional 9,485,000 units at a price of $0.20 per unit. The gross proceeds were $1,897,000 and the proceeds will be used for facility expansion and general corporate purposes. Each unit consists of one common share and one transferrable share purchase warrant, each warrant exercisable to purchase one common share at $0.26 per share for five years. Securities issued are subject to a four-month hold period under applicable Canadian securities laws and no finders’ fees were paid.
ON BEHALF OF THE BOARD
Lotus Ventures Inc.
Dale McClanaghan, President and CEO
About Lotus Ventures Inc.
Lotus Ventures Inc. (CSE:J) is a licensed cannabis producer under the Cannabis Act and Cannabis Regulations, holding a Standard Cultivation and Sale for Medical Purposes license. The Company’s unique business model combines an upstream financing model with Auxly Cannabis Group Inc. and a downstream licensing model with farmer/grower partners utilizing Lotus technology and intellectual property. The initial 22,500 square foot facility in Spallumcheen, B.C. is a purpose built, state of the art indoor facility with proprietary cultivation processes.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), today announced the closing of its previously announced marketed public offering of 5,000,000 subordinate voting shares in the United States and Canada (the “Offering”) at a public offering price of C$50.00 per share ( $39.63 per share after giving effect to the conversion rate published by Bloomberg at 4:30pm ET on April 7, 2021 to convert Canadian dollars to U.S. dollars). In connection with the closing of the Offering, the underwriters exercised in full their option to purchase an additional 750,000 subordinate voting shares. As a result, the gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by Trulieve, were C$287.5 million (or $227.9 million after giving effect to the conversion rate denoted above).
The Offering was conducted through a syndicate of underwriters led by Canaccord Genuity, as sole book-running manager, and included Cormark Securities Inc., as co-lead manager, as well as ATB Capital Markets Inc., Echelon Wealth Partners Inc., Eight Capital and PI Financial Corp. All of the shares in the Offering were sold by Trulieve. Trulieve intends to use the net proceeds from the Offering primarily to fund Trulieve’s business development and for general working capital purposes.
Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that the Company intends to complete a non-brokered private placement (the “Financing” ) of up to 2,645,503 units (the “Units” ) at a price of $0.189 per Unit. Each Unit will consist of one common share ( “Common Share” ) of the Company and one-half of a common share purchase warrant ( “Warrant” ), with each whole Warrant entitling the holder to acquire one additional Common Share at an exercise price of $0.38 per Common Share for a period of 36 months from the closing date ( “Closing Date” ) of the Financing, for gross proceeds of up to $500,000 .
The Company will have an option, prior to the closing date, to upsize the offering with the sale of an additional 25% of Units, accounting to aggregate proceeds of up to $625,000.
Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference
Nextleaf Solutions Receives Amendment to Standard Processing Licence to Allow for Direct to Province Sales
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary, Nextleaf Labs Ltd. (“Nextleaf Labs”), has received an amendment to its existing Standard Cannabis Processing Licence from Health Canada (the “Amendment” or the “Amended Licence”) that authorizes the sale of cannabis extracts, edibles, and topical products, directly to provincially-authorized distributors and retailers across Canada.